Apogee Therapeutics Inc (NASDAQ:APGE) price on current trading day, rose 10.46% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $31.80.
A look at the stock’s price movement, the close in the last trading session was $28.79, moving within a range at $27.15 and $32.82. Turning to its 52-week performance, $63.50 and $26.20 were the 52-week high and 52-week low respectively. Overall, APGE moved -21.03% over the past month.
Apogee Therapeutics Inc’s market cap currently stands at around $1.89 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-02.
Turning to the stock’s technical picture we see that short term indicators suggest on average that APGE is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
APGE’s current price about -15.08% and -13.43% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.48, while 7-day volatility ratio is 16.26% and 8.45% in the 30-day chart. Further, Apogee Therapeutics Inc (APGE) has a beta value of 1.92, and an average true range (ATR) of 3.35. Analysts have given the company’s stock an average 52-week price target of $95, forecast between a low of $95 and high of $95. Looking at the price targets, the low is -198.74% off current price level while to achieve the yearly target high, price needs to move -198.74%. Nonetheless, investors will most likely welcome a -198.74% jump to $95 which is the analysts’ median price.
If we refocus on Apogee Therapeutics Inc (NASDAQ:APGE), historical trading data shows that trading volumes averaged 0.9 over the past 10 days and 686.15K over the past 3 months. The company’s latest data on shares outstanding shows there are 45.99 million shares.
The 37.92% of Apogee Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 81.96% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.16 million on 2025-03-14, giving us a short ratio of 10.72. The data shows that as of 2025-03-14 short interest in Apogee Therapeutics Inc (APGE) stood at 2047.0 of shares outstanding, with shares short falling to 8.32 million registered in 2025-02-14. Current price change has pushed the stock -29.80% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the APGE stock continues to rise going into the next quarter.
